Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer�...
TOKYO - Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer’s treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer’s drug, aducanumab.
The demise of aducanumab came after independent experts determined the trials had little hope of succeeding, marking the latest setback in the quest to treat a mind-wasting disease that affects 5.7 million people in the United States alone. BAN2401 has been met with scepticism since the partners reported promising but confusing 18-month results in July. Yet Eisai remains confident in its continued development.
Alzheimer’s treatments are known as being particularly difficult to develop, as both diagnosis and the recruitment of appropriate trial participants are challenging.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Biogen scraps two Alzheimer drug trials, wipes $18 billion from market valueBiogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their ex...
Baca lebih lajut »
Biogen scraps Alzheimer drug trials, wiping $17 billion off its market valueReuters - Biogen and partner Eisai Co Ltd are ending two late-stage trials for t...
Baca lebih lajut »
Biogen scraps Alzheimer drug trials, shares slump by a quarterBiogen and partner Eisai Co Ltd are ending two late-stage trials testing the exp...
Baca lebih lajut »
Shares of Japan's Eisai swamped with sell orders after ending Alzheimer trialsEisai Co Ltd's shares were untraded on Friday, hit with a glut of sell orde...
Baca lebih lajut »
Biogen's stock plummets after phase 3 trial of Alzheimer's treatment discontinuedShares of Biogen Inc. plummeted 26% toward a near 3-year low in premarket trade Thursday, after the biotechnology company and Japan's Eisai Co. Ltd. said...
Baca lebih lajut »
Biogen is crashing after scrapping its late-stage Alzheimer's drug trialsBiogen shares crashed more than 25% in pre-market trading after discontinuing two late-stage Alzheimer's drug trials with Eisai.
Baca lebih lajut »
Shares of Japan's Eisai swamped with sell orders after ending Alzheimer trialsEisai Co Ltd's shares were untraded on Friday, hit with a glut of sell orde...
Baca lebih lajut »
Biogen scraps two Alzheimer drug trials, wipes $18 billion from market valueBiogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their ex...
Baca lebih lajut »
Biogen's stock plummets after phase 3 trial of Alzheimer's treatment discontinuedShares of Biogen Inc. plummeted 26% toward a near 3-year low in premarket trade Thursday, after the biotechnology company and Japan's Eisai Co. Ltd. said...
Baca lebih lajut »